By Fineline Cube Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its Category 1 therapeutic biologic, SHR-A2102, has received Breakthrough Therapy Designation (BTD) from China’s National Medical Products Administration (NMPA). This is the second BTD for the asset, following a prior designation in December 2024 for urothelial carcinoma.
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) |
| Agency | National Medical Products Administration (NMPA), China |
| Asset | SHR-A2102 (Category 1 Therapeutic Biologic) |
| New Indication (BTD) | Recurrent or metastatic cervical cancer post platinum-based chemo and PD-(L)1 inhibitor failure |
| Previous Indication (BTD) | Locally advanced or metastatic urothelial carcinoma (Dec 2024) |
| Molecule Type | In-house developed Antibody-Drug Conjugate (ADC) |
| Target | Nectin-4 |
Clinical Development Portfolio
SHR-A2102 is a cornerstone of Hengrui’s oncology pipeline, with an expansive clinical program spanning Phase I to Phase III trials across multiple solid tumor types, including:
- Advanced urothelial carcinoma / bladder cancer
- Esophageal cancer
- Lung cancer
- Head and neck cancer
- Cervical cancer
The BTD for cervical cancer specifically addresses a critical unmet need for patients who have exhausted standard-of-care options, including chemotherapy and immunotherapy. Nectin-4, a well-validated target in urothelial cancer (e.g., enfortumab vedotin), is also expressed in a significant subset of cervical cancers, providing a strong scientific rationale for this expansion.
Strategic Significance
Securing a second BTD for the same ADC asset underscores the strength of Hengrui’s internal R&D capabilities and the broad therapeutic potential of SHR-A2102. The NMPA’s BTD status facilitates an expedited review process, potentially accelerating the drug’s path to market for both key indications. This dual-indication strategy significantly enhances the asset’s commercial value and positions Hengrui as a leader in the next generation of targeted oncology therapies in China.
Forward-Looking Statements
This brief contains forward-looking statements regarding the development and regulatory pathway of SHR-A2102. The granting of BTD does not guarantee approval, and clinical trial outcomes remain subject to risk.-Fineline Info & Tech